Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis

Chertow, Glenn M;Block, Geoffrey A;Correa-Rotter, Ricardo;Drüeke, Tilman B;Jadoul, Michel;et.al.
(2012) The New England journal of medicine — Vol. 367, n° 26, p. 2482-2494 (2012)

Files

EvolveTrialInvestigatorsChertowGMetalEdffectofcinacalcetoncardiovasculardiseaseinptaientsundergoingdialysisNEJM2012.pdf
  • Restricted Access
  • Adobe PDF
  • 1.31 MB
Request a copy

Details

Authors
  • Chertow, Glenn M
    Author
  • Block, Geoffrey A
    Author
  • Correa-Rotter, Ricardo
    Author
  • Drüeke, Tilman B
    Author
  • Jadoul, MichelUCLouvain
    Collaborator
Show more
Abstract
In an unadjusted intention-to-treat analysis, cinacalcet did not significantly reduce the risk of death or major cardiovascular events in patients with moderate-to-severe secondary hyperparathyroidism who were undergoing dialysis. (Funded by Amgen; EVOLVE ClinicalTrials.gov number, NCT00345839.).
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Chertow, G. M., Block, G. A., Correa-Rotter, R., Drüeke, T. B., Floege, J., Goodman, W. G., Herzog, C. A., Kubo, Y., London, G. M., Mahaffey, K. W., Mix, T. C. H., Moe, S. M., Trotman, M.-L., Wheeler, D. C., Parfrey, P. S., & EVOLVE Trial Investigator. (2012). Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. The New England journal of medicine, 367(26), 2482-2494. https://doi.org/10.1056/NEJMoa1205624 (Original work published 2012)